H.C. Wainwright recorded Galectin Therapeutics (NASDAQ:GALT), upping its target price to $1.50 today
- Updated: September 28, 2016
H.C. Wainwright bumped up the target of Galectin Therapeutics (NASDAQ:GALT) to $1.50 reporting a potential upside of 0.07%.
Only yesterday Galectin Therapeutics (NASDAQ:GALT) traded -38.06% lower at $1.40. The company’s 50-day moving average is $1.92 and its 200-day moving average is $1.61. With the last stock price close down -4.88% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trading volume was up over the average, with 4,043,076 shares of GALT changing hands over the typical 417,641
Recent Performance Chart
Galectin Therapeutics has with a one year low of $1.08 and a 52 week high of $3.25 and has a market cap of $0.
A total of 3 firms have reported on Galectin Therapeutics. One equity analyst rating the stock a strong buy, 2 analysts rating the company a buy, 0 brokers rating the company a hold, zero firms rating the stock a underperform, and finally zero analysts rating the company a sell with a average stock price target of $8.33.
General Company Details For Galectin Therapeutics (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.